Abstract

Objective: In High Dose Rate Brachytherapy for prostate cancer there is a need for a new way of increasing cancer cell kill in combination with a stable dose to the organs at risk. In this study, we propose a novel ThermoBrachy applicator that offers the unique ability to apply interstitial hyperthermia while simultaneously serving as an afterloading catheter for high dose rate brachytherapy for prostate cancer. This approach achieves a higher thermal enhancement ratio than in sequential application of radiation and hyperthermia and has the potential to decrease the overall treatment time. Methods: The new applicator uses the principle of capacitively coupled electrodes. We performed a proof of concept experiment to demostrate the feasibility of the proposed applicator. Moreover, we used electromagnetic and thermal simulations to evaluate the power needs and temperature homogeneity in different tissues. Furthermore we investigated whether dynamic phase and amplitude adaptation can be used to improve longitudinal temperature control. Results: Simulations demonstrate that the electrodes achieve good temperature homogeneity in a homogenous phantom when following current applicator spacing guidelines. Furthermore, we demonstrate that dynamic phase and amplitude adaptation provides a great advancement for further adaptability of the heating pattern. Conclusions: This newly designed ThermoBrachy applicator has the potential to revise the interest in interstitial thermobrachytherapy, since the simultaneous application of radiation and hyperthermia enables maximum thermal enhancement and provides maximum efficiency for patient and organization.

Highlights

  • High Dose Rate Brachytherapy (HDR-BT) is a valuable treatment option for prostate cancer mainly due to its ability to deliver high radiation dose preferential to the target

  • We propose a novel ThermoBrachy applicator that offers the unique ability to apply interstitial hyperthermia while simultaneously serving as an afterloading catheter for high dose rate brachytherapy for prostate cancer

  • It can be observed that simulation and experiment lead to similar heating patterns, though with small variations caused by the irregularities in the shape of the handcrafted applicator

Read more

Summary

Introduction

High Dose Rate Brachytherapy (HDR-BT) is a valuable treatment option for prostate cancer mainly due to its ability to deliver high radiation dose preferential to the target. Ultra-hypofractionated HDR-BT has several potential advantages, such as a lower patient burden due to shorter hospitalization and a shorter overall treatment time. These advantages apply to locally recurrent prostate cancer after primary radiation therapy, in which salvage HDR-BT is a good treatment option [6,7,8]. These developments indicate that there is a need for a new way of increasing cancer cell kill without increasing the dose delivered to the organs at risk, or even better, while lowering the dose to the organs at risk

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.